

and patient can both agree on an individualised action plan aimed at adjusting therapy to minimise any clearly visible low or high glucose patterns, which should result in more glucose values that are in the target range.

Richard M Bergenstal

International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA

richard.bergenstal@parknicollet.com


I have received research support, consulted, or been on the scientific advisory board for Abbott Diabetes Care, DexCom, Johnson & Johnson, Medtronic, Onduo, Roche, Sanofi, and United Healthcare. My technology research is partly funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH grant DK108611). I am a volunteer for the American Diabetes Association, American Association of Clinical Endocrinologists, and JDRF. My employer, non-profit HealthPartners Institute, contracts for my services and I receive no personal income. I have inherited Merck stock. Merck does not manufacture or distribute any products related to the Article being discussed in this Comment.

- 1 Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. *Diabetes Care* 2017; **40**: 994–99.
- 2 Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. *Nat Rev Endocrinol* 2014; **10**: 711–22.
- 3 Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. *Diabetes* 2014; **63**: 2188–95.
- 4 Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! *Diabetes Care* 2015; **38**: 1615–21.

- 5 Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. *Lancet* 2018; published online Feb 16. [http://dx.doi.org/10.1016/S0140-6736\(18\)30297-6](http://dx.doi.org/10.1016/S0140-6736(18)30297-6).
- 6 Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. *JAMA* 2016; **316**: 1407–08.
- 7 Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. *JAMA* 2013; **310**: 1240–47.
- 8 van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. *Lancet Diabetes Endocrinol* 2016; **4**: 893–902.
- 9 Beck RW, Riddlesworth T, Ruedy K, et al, for the DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. *JAMA* 2017; **317**: 371–78.
- 10 Aleppo G, Laffel LM, Ahmann AJ, et al. A practical approach to using trend arrows on the Dexcom G5 CGM system for the management of adults with diabetes. *J Endocr Soc* 2017; **1**: 1445–60.
- 11 Feig DS, Donovan LE, Corcoy R et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicenter international randomized controlled trial. *Lancet* 2017; **390**: 2347–59.
- 12 Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. *Diabetes Technol Ther* 2017; **19**: S4–11.
- 13 Fradkin JE, Hanlon MC, Rodgers GP. NIH precision medicine initiative: implications for diabetes research. *Diabetes Care* 2016; **39**: 1080–84.
- 14 Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. *Diabetes Care* 2017; **40**: 1631–40.



Widening the options for recurrent malaria



The global need for new antimalarial drugs and new combinations is enormous and urgent,^{1,2} but their successful delivery needs resilience to overcome the barriers imposed by expensive and lengthy clinical development plans. Attention is often directed to areas such as southeast Asia, where some antimalarial combinations are failing but transmission intensities are much lower than in sub-Saharan African countries. Children in Africa have frequent and life-threatening malaria infections as they grow up, and these need to be treated safely.

Pyronaridine-artesunate and dihydroartemisinin-piperaquine are two artemisinin combination therapies (ACTs) that exemplify the challenges that arise in the pathway towards licensure and wider implementation. These two drug combinations have a good track record of efficacy^{3,4} and are approved by the European Medicines Agency (EMA). However, their introduction into first-line therapies in malaria-endemic countries, particularly in sub-Saharan Africa where the global malaria problem is worst, has been sporadic and slow.

Questions about the safety of ACTS (ie, hepatotoxicity for pyronaridine-artesunate and cardiotoxicity for dihydroartemisinin-piperaquine) might have delayed their endorsement by WHO,⁵ thereby obstructing adoption into national malaria-control programmes. They are also needed in southeast Asia where other antimalarial treatments are no longer effective when used in conventional doses.⁶

Adequate assessment of antimalarial drugs should not be restricted to investigating their ability to cure a single infection safely, but to rather account for their overall efficacy in decreasing the long-term cumulative incidence of disease and their prolonged safety when used repeatedly. In high-transmission, malaria-endemic areas, repeated symptomatic malaria infections are common until the acquisition of a degree of immunity against the disease. In highly endemic vivax transmission areas, relapses caused by hypnozoites frequently contribute to repeated clinical episodes of malaria. In *The Lancet*, Issaka Sagara and colleagues from the West African Network for Clinical Trials of Antimalarial

Published Online

March 29, 2018

[http://dx.doi.org/10.1016/S0140-6736\(18\)30630-5](http://dx.doi.org/10.1016/S0140-6736(18)30630-5)

See [Articles](#) page 1378

Drugs (WANECAM) provide reassuring results on the safety and efficacy of pyronaridine-artesunate and dihydroartemisinin-piperaquine in a large, randomised, controlled trial undertaken in Mali, Burkina Faso, and Guinea.⁷ For 2 years they followed up a longitudinal cohort of 4710 adult and paediatric patients aged 6 months and older with microscopically confirmed *Plasmodium* spp malaria to assess the safety and efficacy of pyronaridine-artesunate and dihydroartemisinin-piperaquine to treat recurrent malaria versus current recommended first-line (re)treatments with artemether-lumefantrine or artesunate-amodiaquine. All treatments were once-daily or twice-daily tablets or granules given orally over 3 days at the study centres, and patients were followed up as outpatients up to day 42.

The results of this large and complex trial⁷ confirmed the non-inferiority of both pyronaridine-artesunate and dihydroartemisinin-piperaquine against the comparators for the primary endpoints of (1) 2-year malaria incidence rate in the intention-to-treat population (pyronaridine-artesunate vs artemether-lumefantrine [1.77, 95% CI 1.63–1.93 vs 1.87, 1.72–2.03; rate ratio (RR) 1.05, 95% CI 0.94–1.17] and vs artesunate-amodiaquine [1.39, 95% CI 1.22–1.59 vs 1.35, 1.18–1.54; RR 0.97, 0.87–1.07]; dihydroartemisinin-piperaquine vs artemether-lumefantrine [1.16, 95% CI 1.01–1.34 vs 1.42, 1.25–1.62; RR 1.22, 95% CI 1.06–1.41] and vs artesunate-amodiaquine [1.35, 1.21–1.51 vs 1.68, 1.51–1.88; RR 1.25, 1.02–1.50]); and (2) adequate clinical and parasitological response in uncomplicated malaria across all episodes assessed in the per-protocol population on days 28 and 42 (for *P falciparum* malaria, PCR-adjusted adequate clinical and parasitological response was greater than 99.5% at day 28 and greater than 98.6% at day 42 for all ACTs).

These findings highlight that all four ACTs are robust in some of the highest pockets of malaria transmission globally and they exemplify the cumulative advantages of using drug combinations that include partner drugs with longer elimination half-lives, such as piperaquine (around 4 weeks in dihydroartemisinin-piperaquine) or pyronaridine (10–13 days in pyronaridine-artesunate). Indeed, the crude effects of dihydroartemisinin-piperaquine on the 2-year incidence of malaria compared with artemether-lumefantrine or artesunate-amodiaquine probably reflect the better long-term and cumulative effects of post-treatment prophylaxis with piperaquine in preventing new infections, a finding that

has implications for the current malaria-elimination agenda.⁸

Additionally, the WANECAM study⁷ confirmed the good tolerability of single and repeated treatments of pyronaridine-artesunate and dihydroartemisinin-piperaquine. For pyronaridine-artesunate, this finding ratifies the revision in 2015⁹ of the initial 2012 EMA approval,¹⁰ which originally limited the treatment possibilities both individually (to just once in a lifetime) and geographically (to low-endemic settings with high risk of artemisinin resistance). The 2015 revision has removed all restrictions on repeat dosing, on use only in areas of high resistance and low transmission, and on requirements for liver function monitoring. The results from the WANECAM study⁷ should enable rapid inclusion of pyronaridine-artesunate into WHO's malaria treatment guidelines.⁵

The WANECAM trial did confirm an increased risk of liver transaminitis in some recipients of pyronaridine-artesunate. However, the absence of any clinical implication, the transient nature of the increases in all cases, and the absence of an incremental effect in those receiving repeated doses are reassuring, and support the wider use of pyronaridine-artesunate for the treatment of malaria. The safety of pyronaridine-artesunate should continue to be monitored, including its use in HIV-infected individuals, as this particularly vulnerable population was excluded from participating in the trial—an important limitation for the generalisation of the results. A large study of pyronaridine-artesunate in which HIV infection is not an exclusion criterion is ongoing (NCT03201770).

The WANECAM trial also shed light on other safety concerns, particularly prolongation of the QT interval and the consequent increased risk of life-threatening arrhythmias. The findings suggested that the incidence of QTcF prolongation was higher after dihydroartemisinin-piperaquine versus artemether-lumefantrine and pyronaridine-artesunate, but no differences were noted between dihydroartemisinin-piperaquine and artesunate-amodiaquine. There were no clinical symptoms or complications associated with the prolongation, and retreatment did not seem to make these findings worse, although the numbers studied were small.

Manufacturers recommend that dihydroartemisinin-piperaquine should be taken under fasting conditions to minimise the risks of a food effect that increases plasma

concentrations of piperaquine and cardiac effects. In the WANECAM study,⁷ dihydroartemisinin–piperaquine was administered without first imposing a fast, providing further reassurance about safety. The results from this study are also consistent with the opinions of an expert panel convened by WHO to review the cardiotoxicity of antimalarial drugs,¹¹ and with the conclusions of a meta-analysis reviewing the safety of repeated use of dihydroartemisinin–piperaquine.¹² They further support the continued use of dihydroartemisinin–piperaquine in malaria-endemic areas.

Rigorous safety assessments of any new drug are necessary to safeguard patients. Generally, risk-benefit analyses of antimalarial drugs also need to account for the life-threatening potential and continuing morbidity associated with malaria. The findings from the WANECAM study support upscaling the use of pyronaridine–artesunate and dihydroartemisinin–piperaquine in sub-Saharan Africa so that they can contribute even more effectively to the global fight against malaria.

**Quique Bassat, Sanjeev Krishna*

Barcelona Institute for Global Health, ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona 08036, Spain; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; ICREA, Pg Lluís Companys 23, Barcelona, Spain; and Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain (QB); Centre for Diagnostics and Antimicrobial Resistance, Institute for Infection & Immunity, St George's University of London, London, UK; Institut für Tropenmedizin Universitätsklinikum Tübingen, Tübingen, Germany; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon; and St George's University Hospitals NHS Foundation Trust, London, UK (SK)
quique.bassat@isglobal.org

We are both members of the WHO Malaria Treatment Guidelines Group. This group produces global guidance on the treatment of malaria and this includes decisions about pyronaridine–artesunate. The views expressed by the authors are personal opinions and do not represent the recommendations of WHO.

Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

- 1 Chirac P, Torreele E. Global framework on essential health R&D. *Lancet* 2006; **367**: 1560–61.
- 2 Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a glass half full? *Nat Rev Drug Discov* 2015; **14**: 424–42.
- 3 Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair S, Tharyan P. Artesunate plus pyronaridine for treating uncomplicated *Plasmodium falciparum* malaria. *Cochrane Database Syst Rev* 2014; **3**: CD006404.
- 4 Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin–piperaquine for treating uncomplicated *Plasmodium falciparum* malaria. *Cochrane Database Syst Rev* 2014; **1**: CD010927.
- 5 WHO. Guidelines for the treatment of malaria, third edn. Geneva: World Health Organization; 2015.
- 6 Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in southeast Asia and the potential for future spread. *FEMS Microbiol Rev* 2017; **41**: 34–48.
- 7 The West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. *Lancet* 2018; published online March 29. [http://dx.doi.org/10.1016/S0140-6736\(18\)30291-5](http://dx.doi.org/10.1016/S0140-6736(18)30291-5).
- 8 Bassat Q, Menendez C. Dihydroartemisinin–piperaquine: if it works for control, can we use it for elimination? *Lancet Infect Dis* 2017; **17**: 121–22.
- 9 Committee for Medicinal Products for Human Use summary of opinion. Pyramax: pyronaridine–artesunate, 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_for_use_outside_EU/2015/11/WC500196738.pdf (accessed Feb 24, 2018).
- 10 Committee for Medicinal Products for Human Use. Pyramax: pyronaridine tetraphosphate/artesunate, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_for_use_outside_EU/2012/02/WC500122945.pdf (accessed Feb 24, 2018).
- 11 WHO. WHO evidence review group on the cardiotoxicity of antimalarial medicines. Geneva: World Health Organization, 2017.
- 12 Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin–piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**: 184–93.



A milestone for palliative care and pain relief

Published Online
October 12, 2017
[http://dx.doi.org/10.1016/S0140-6736\(17\)32560-6](http://dx.doi.org/10.1016/S0140-6736(17)32560-6)

See [The Lancet Commissions](#) page 1391

Universal health coverage (UHC) has assumed an iconic place in work to achieve the Sustainable Development Goals (SDGs). Its central importance for achieving SDG 3—ensuring healthy lives for all—is proven by the increasingly sophisticated efforts to measure UHC and to estimate to what extent UHC can be achieved by 2030. An example is the Global Burden of Disease (GBD).¹ The GBD team constructed a UHC Index by beginning with the idea of access to quality essential health-care services and access to safe, effective, quality,

and affordable essential medicines and vaccines. They then took a collection of tracer indicators, including for vaccines, antenatal care, skilled birth attendance, facility births, antiretroviral coverage, and treatments for several diseases amenable to personal health care. The GBD's UHC Index was based on a comprehensive assessment of these components. Palliative care and pain relief were not among these measures.

Palliative care and pain relief are some of the most neglected dimensions of global health today. They are